EUVIMEDEUVIMED entdecken
Kohortenstudie

Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study

Guangtong Deng iD, Daishi Li, Yuming Sun, Liping Jin, Qian Zhou, Chenggen Xiao, Qingrong Wu, Huiyan Sun, Yating Dian, Furong Zeng iD, Pinhua Pan iD, Minxue Shen

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28756 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Guangtong Deng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chinese guidelines prioritize the use of Azvudine and nirmatrelvir–ritonavir in COVID‐19 patients. Nevertheless, the real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir is still lacking, despite clinical trials showing their effectiveness compared with matched controls. To compare the effectiveness of Azvudine versus nirmatrelvir–ritonavir treatments in real‐world clinical practice, we identified 2118 hospitalized COVID‐19 patients, with a follow‐up of up to 38 days. After exclusions and propensity score matching, we included 281 Azvudine recipients and 281 nirmatrelvir–ritonavir recipients who did not receive oxygen therapy at admission. The lower crude incidence rate of composite disease progression outcome (7.83 vs. 14.83 per 1000 person‐days, p = 0.026) and all‐cause death (2.05 vs. 5.78 per 1000 person‐days, p = 0.052) were observed among Azvudine recipients. Azvudine was associated with lower risks of composite disease progression outcome (hazard ratio [HR]: 0.55; 95% confidence interval [CI]: 0.32–0.94) and all‐cause death (HR: 0.40; 95% CI: 0.16–1.04). In subgroup analyses, the results of composite outcome retained significance among patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansCOVID-19 Drug TreatmentRetrospective StudiesRitonavirDisease ProgressionAntiviral AgentsAzidesDeoxycytidineLactamsLeucineNitrilesProline

Stichwörter der Autor:innen

AzvudineCOVID-19all-cause deathcomposite disease progression outcomenirmatrelvir-ritonavirreal-world evidence

Substanzen

RitonavirAntiviral AgentsazvudineAzidesDeoxycytidinenirmatrelvirLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
  • National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China.
  • Furong Laboratory, Changsha, Hunan, China.
  • Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China.
  • Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Guangtong Deng, Furong Zeng, Pinhua Pan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Deng, G., Li, D., Sun, Y., Jin, L., Zhou, Q., Xiao, C., Wu, Q., Sun, H., Dian, Y., Zeng, F., Pan, P., & Shen, M. (2023). Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study. Journal of Medical Virology. https://doi.org/10.1002/jmv.28756

Vancouver

Deng G, Li D, Sun Y, Jin L, Zhou Q, Xiao C, et al. Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study. Journal of Medical Virology. 2023. doi:10.1002/jmv.28756

BibTeX
@article{Deng2023,
  author = {Deng, Guangtong and Li, Daishi and Sun, Yuming and Jin, Liping and Zhou, Qian and Xiao, Chenggen and Wu, Qingrong and Sun, Huiyan and Dian, Yating and Zeng, Furong and Pan, Pinhua and Shen, Minxue},
  title = {Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28756}
}
Kostenlos starten →